KORU Medical Systems Inc Dossier
Qualitative Analysis
Business overview
KORU Medical Systems, Inc. (NASDAQ: KRMD), formerly known as Repro Med Systems, Inc., is a leading medical technology company that designs, manufactures, and commercializes patient-centric, large-volume subcutaneous infusion solutions. The company's flagship product line is the Freedom Infusion System, which includes the FREEDOM60® and FreedomEdge® Syringe Drivers, HIgH-Flo Subcutaneous Safety Needle Sets, and Precision Flow Rate Tubing. These mechanical, battery-free devices are primarily used for the self-administration of subcutaneous immunoglobulin (SCIg) therapies at home or in outpatient settings for patients with chronic illnesses such as Primary Immunodeficiency Diseases (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). KORU Medical operates as a single business segment, generating revenue through three primary streams: Domestic Core, International Core, and Pharma Services and Clinical Trials.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Driving domestic and international market share gains in subcutaneous immunoglobulin (SCIg) therapy, specifically focusing on converting patients from vial-based delivery to prefilled syringes (PFS). This shift simplifies administration and reduces drug preparation tasks by up to 80%.
Expected impact: Sustained double-digit growth in the core business, outperforming the broader SCIg market growth rate of 8-10%.
Expanding the utility of the Freedom Infusion System into non-Ig therapeutic areas such as oncology (e.g., Phesgo), hematology (e.g., Deferoxamine), and neurology (e.g., RYSTIGGO).
Expected impact: Diversification of the revenue base and expansion of the total addressable market by targeting a pipeline of over 95 subcutaneous drugs currently in development.
Partnering with biopharmaceutical companies to qualify the Freedom System for clinical trials and commercial drug delivery. The company targeted four new pipeline collaborations for fiscal year 2026.
Expected impact: Securing non-recurring engineering (NRE) revenues and establishing long-term commercial drug delivery partnerships. Two of the four targeted collaborations were already signed as of Q1 2026.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Broad collaboration on next-generation infusion systems in subcutaneous immunoglobulin (SCIg) therapy for both commercial drugs and clinical programs, qualifying an infusion system that accommodates both vials and prefilled syringes using SCHOTT TOPPAC polymer syringes.
Terms: Not disclosed
Leveraging KORU's FreedomEDGE infusion system as part of ForCast's Wearable Intra-Articular Infusion System (WIIS) platform for targeted antibiotic treatment of periprosthetic joint infections (PJI).
Terms: Not disclosed